I'll remember the people who died suffering from lung cancer.
A new drug came out of Korea. First U.S. FDA Approved for Korean Anti-cancer Drugs
유한양행 폐암 신약,
美 FDA 승인…
국산 항암제 최초
Yuhan Corporation’s new drug for lung cancer,
Approved by the US FDA…
The first domestically produced anticancer drug

Yuhan Corporation's Lung Cancer Drug 'LECLAZA' in combination with 'RYBREVANT' Receives First U.S. Food and Drug Administration Approval
유한양행 폐암치료제 '렉라자'와 '라이브레반트' 병용, 미국 식품의약국(FDA) 최초 승인 획득
https://www.thebionews.net/news/articleView.html?idxno=8021
Yuhan Corporation's Lung Cancer Drug 'LECLAZA' in combination with 'RYBREVANT' Receives First U.S. Food and Drug Administration
[by Yoo, Ha Eun] The U.S. Food and Drug Administration (FDA) has approved Yuhan Corporation’s LECLAZA (US product name: LAZCLUZE) in combination with Johnson &
www.thebionews.net
https://www.thebionews.net/news/articleView.html?idxno=8021
Yuhan Corporation's Lung Cancer Drug 'LECLAZA' in combination with 'RYBREVANT' Receives First U.S. Food and Drug Administration
[by Yoo, Ha Eun] The U.S. Food and Drug Administration (FDA) has approved Yuhan Corporation’s LECLAZA (US product name: LAZCLUZE) in combination with Johnson &
www.thebionews.net
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment fo
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus...
www.prnewswire.com
유한양행, '렉라자' 美 FDA 허가 소식에 12%대 급등[핫스탁]
유한양행이 비소세포폐암 치료제 렉라자의 미국 식품의약국(FDA) 허가 소식에 장 초반 급등세다. 21일 한국거래소에 따르면 오전 9시3분 현재 유한양행은 전일 대비 1만1700원(12.45%) 오른 10만5700원
n.news.naver.com
'관심거리 Interests' 카테고리의 다른 글
전기료 30만원이상 19만 가구 (0) | 2024.09.10 |
---|---|
오래 쓴 나무젓가락 버려야 4인가족 잇따라 간암 사망 (0) | 2024.08.27 |
[날씨] 한반도 향하는 첫 태풍...세력 약해도 "방심은 금물" (0) | 2024.08.20 |
여의도 하늘에 '서울달' 떴다…130m 상공 비행,서울워커 (0) | 2024.08.15 |
뱃속 태아까지 해부 일본노병, 일본 731부대 만행 사죄 (0) | 2024.08.14 |